The DPT is aimed at determining whether it is possible to prevent or delay the onset of type 1 diabetes in individuals determined to be at immunologic, genetic, and/or metabolic risk. The program also supports the Epidemiology of Diabetes Interventions and Complications study, an epidemiologic follow-up study of the subjects previously enrolled in the Diabetes Control and Complications Trial (DCCT).
Notice, Released July 13, 1999
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces that a portion (1/3) of all stored non-renewable samples (plasma, serum, urine) from subjects enrolled in the Diabetes Control and Complications Trial (DCCT) is available for use by the scientific community to address questions for which these samples are uniquely invaluable.
For further information contact Catherine Cowie, Director, Type 1 Diabetes Clinical Trials Program, phone: (301) 594-8804, fax: (301) 480-3503).
Type 2 Diabetes Clinical Trials Program
The Type 2 Diabetes Clinical Trials Program supports large, multi-center clinical trials conducted under cooperative agreements or contracts. One primary prevention trial is underway. The Diabetes Prevention Program (DPP) is focused on testing lifestyle and pharmacological intervention strategies in individuals at genetic and metabolic risk for developing type 2 diabetes to prevent or delay the onset of this disease. At this time, the recruitment goals have been reached and new patients are not being enrolled.
For further information contact Sanford Garfield, Senior Advisor for Biometry and Behavioral Research.
Studies of Health Outcomes of Weight-loss (SHOW) Trial
For further information, contact Mary Evans, Ph.D.
See the NIDDK Clinical Trials page for a complete list.
